ITonis

ITonis Net Change in Cash

The Net Change in Cash of ITonis (ITNS) as of Nov 11, 2026 is -295.00 USD. In the previous year, Net Change in Cash was -2,763.00 USD — a change of -89.32% (higher).

Net Change in Cash

-295.00USD

YoY

-89.32%

Last updated:

Net Change in Cash of ITonis is 2023 -295.00 USD. Net Change in Cash of ITonis was 2022 -2,763.00 USD. It decreases by -89.32% higher compared to the previous year.

The ITonis Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2016
7,419.00 USD
Jan 1, 2017
5,510.00 USD
Jan 1, 2018
-10,249.00 USD
Jan 1, 2019
-2,852.00 USD
Jan 1, 2020
51.00 USD
Jan 1, 2021
1,352.00 USD
Jan 1, 2022
-2,763.00 USD
Jan 1, 2023
-295.00 USD
The ITonis Net Change in Cash history
YEARNet Change in CashYoY
-295.00USD-89.32%
-2,763.00USD-304.36%
1,352.00USD+2,550.98%
51.00USD-101.79%
-2,852.00USD-72.17%
-10,249.00USD-286.01%
5,510.00USD-25.73%
7,419.00USD-1,797.71%
-437.00USD-247.14%
297.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ITonis Stock analysis

What does ITonis do? Itonis, Inc. generates revenue through the distribution of its homeopathic anti-nausea product Emesyl to the medical and pharmaceutical industry. The company markets Emesyl, an over-the-counter and prescription homeopathic preparation, primarily targeting the general public suffering from nausea. Sales occur via Amazon and the company's website Emesyl.com. The firm's subsidiaries, Itonis Holdings, Inc. and Paramount Discoveries, Inc., support its operations in the pharmaceutical sector. Emesyl is positioned as a solution for common ailments, with its availability on Amazon and Emesyl.com enabling direct consumer access. The company's focus on both over-the-counter and prescription products allows it to serve diverse customer segments within the healthcare market. Itonis Pharmaceuticals division handles the production and marketing of these homeopathic preparations. The business model relies on the sale of Emesyl through established retail channels and direct online sales, leveraging the brand's presence on Amazon and its dedicated website. This approach targets individuals seeking nausea relief without requiring a prescription, aligning with the product's over-the-counter status and broad market appeal. ITonis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ITonis stock

Net Change in Cash of ITonis is -295.00 USD in 2023.

Net Change in Cash of ITonis changed from -2,763.00 USD to -295.00 USD, representing a -89.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash ITonis since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's ITonis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ITonis

All Key Metrics — ITonis